MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia

por Rabello, Doralina do Amaral, Ferreira, Vivian D’Afonseca da Silva, Berzoti-Coelho, Maria Gabriela, Burin, Sandra Mara, Magro, Cíntia Leticia, Cacemiro, Maira da Costa, Simões, Belinda Pinto, Saldanha-Araujo, Felipe, de Castro, Fabíola Attié, Pittella-Silva, Fabio
Publicado 2018